用广义上界算法解大型供应链问题

信息技术和生产率的发展以及全球经济一体化的发展趋势，使供应链成为全世界管理科学的热点.本文在阐述供应链基本数学模型的基础上，系统论述了用改进的广义上界(GUB)算法求解大型供应链问题的计算方法．     

Preparation of Perovskite-Type Oxides La1-x Srx Fe1-y Coy O3 Using EDTA Sol-Gel Method

Two series of perovskite-type oxides with composition La1-xSrxFeO3 (x≤0.8)and La1-xSrxFe1-yCoyO3( x = 0.2；y = 0.2, 0.4 ) powder productions were synthesized by EDTA complexing sol-gel method. The products were characterized by XRD, TEM, SEM, BET method (N2 adsorption)and laser granularity analysis for different synthesis conditions to obtain the optimum conditions for the preparation process. Single-phased, uniform perovskite-type oxides with small particle size were obtained by EDTA sol-gel process with high stability and repeatability,and the process temperature is much lower than that of solid state reaction method.     

基于遗传算法的0/1背包问题求解

利用遗传算法提出了解决０／１背包问题的３种算法,这３种算法分别是基于罚函数修正方法和译码方法的算法,理论分析表明,修正方法可以获得问题的最优解,在不同测试数据集上对这３处算法的性能进行了比较,结果与理论分析一致。     

RP-HPLC测定舒胸片中人参皂甙Rg1的含量

运用反相高效液相色谱对舒胸片中的有效成分人参皂甙Rg1进行了分离,并对其进行了含量测定,建立了反相HPLC测定舒胸片中人参皂甙Rg1的含量的方法.色谱柱:AlltimaC18(250mm×4.6mm,5μm),流动相:乙腈水(0.05%磷酸)=2575,流速:0.9mL/min,检测波长:203nm,柱温:35℃.平均回收率为96.5%,RSD为1.40%.     

半不连续切屑流动速度的系统分析及切屑变形的度量

本文借助影片运动分析仪,对用高速摄影记录的钛合金切屑沿前刀面的流动规律进行了研究,并用系统分析法进行了描述,推导出能反映半不连续切屑不均匀变形过程的动态衡量参数,同时也导出了度量此种切屑塑性变形的准静态参数——等效切削比。     

用核糖体工程技术二次开发海洋微生物菌株资源的研究

经对无活性的海洋来源放线菌B3054进行链霉素抗性筛选,获得了一株具有抗肿瘤活性的链霉素抗性突变株SY-1.从该突变株的发酵物中分离得到了4个活性化合物,其中1个为新天然产物.对该菌株突变前后的rpsL基因(编码核糖体蛋白S12)进行分析未发现发生突变,提示突变位点可能在核糖体的另外亚基上.实验结果表明,核糖体工程技术可用于无活性菌株资源的二次开发利用.     

Effect of postmolding heat treatment on in vitro properties of a polyanhydride implant containing gentamicin sulfate

A polyanhydride implant containing gentamicin sulfate was fabricated using a laboratory-scale injection-molding machine. After injection molding, the implants were subject to heat treatment at 60°C for various time periods with or without nitrogen protection. The impact of this heat treatment on the in vitro properties of the implants including copolymer molecular weights, mechanical properties, and in vitro drug-release profiles was investigated. This heat treatment caused a drastic drop in the molecular weight of the copolymer. Heating without nitrogen protection resulted in the hardening of the implant, but heating in the presence of nitrogen rendered the implant less rigid. It was also found that a faster in vitro drug release profile was shown by implants heated without nitrogen protection and a pronounced slowing down in drug release was exhibited by implants heated with nitrogen protection.     

Insights into the Pharmacokinetics and In Vitro Cell-Based Studies of the Imidazoline I2 Receptor Ligand B06

The impact of neurodegenerative diseases (ND) is becoming unbearable for humankind due to their vast prevalence and the lack of efficacious treatments. In this scenario, we focused on imidazoline I₂ receptors (I₂-IR) that are widely distributed in the brain and are altered in patients with brain disorders. We took the challenge of modulating I₂-IR by developing structurally new molecules, in particular, a family of bicyclic α-iminophosphonates, endowed with high affinity and selectivity to these receptors. Treatment of two murine models, one for age-related cognitive decline and the other for Alzheimer’s disease (AD), with representative compound B06 ameliorated their cognitive impairment and improved their behavioural condition. Furthermore, B06 revealed beneficial in vitro ADME-Tox properties. The pharmacokinetics (PK) and metabolic profile are reported to de-risk B06 for progressing in the preclinical development. To further characterize the pharmacological properties of B06, we assessed its neuroprotective properties and beneficial effect in an in vitro model of Parkinson’s disease (PD). B06 rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine (6-OHDA) and showed a crucial anti-inflammatory effect in a cellular model of neuroinflammation. This research reveals B06 as a putative candidate for advancing in the difficult path of drug discovery and supports the modulation of I₂-IR as a fresh approach for the therapy of ND.     

The Cytoskeletal Protein Zyxin Inhibits Retinoic Acid Signaling by Destabilizing the Maternal mRNA of the RXRγ Nuclear Receptor

Zyxin is an LIM-domain-containing protein that regulates the assembly of F-actin filaments in cell contacts. Additionally, as a result of mechanical stress, Zyxin can enter nuclei and regulate gene expression. Previously, we found that Zyxin could affect mRNA stability of the maternally derived stemness factors of Pou5f3 family in Xenopus laevis embryos through binding to Y-box factor1. In the present work, we demonstrate that Zyxin can also affect mRNA stability of the maternally derived retinoid receptor Rxrγ through the same mechanism. Moreover, we confirmed the functional link between Zyxin and Rxrγ-dependent gene expression. As a result, Zyxin appears to play an essential role in the regulation of the retinoic acid signal pathway during early embryonic development. Besides, our research indicates that the mechanism based on the mRNA destabilization by Zyxin may take part in the control of the expression of a fairly wide range of maternal genes.     

Venom Peptide Toxins Targeting the Outer Pore Region of Transient Receptor Potential Vanilloid 1 in Pain: Implications for Analgesic Drug Development

The transient receptor potential vanilloid 1 (TRPV1) ion channel plays an important role in the peripheral nociceptive pathway. TRPV1 is a polymodal receptor that can be activated by multiple types of ligands and painful stimuli, such as noxious heat and protons, and contributes to various acute and chronic pain conditions. Therefore, TRPV1 is emerging as a novel therapeutic target for the treatment of various pain conditions. Notably, various peptides isolated from venomous animals potently and selectively control the activation and inhibition of TRPV1 by binding to its outer pore region. This review will focus on the mechanisms by which venom-derived peptides interact with this portion of TRPV1 to control receptor functions and how these mechanisms can drive the development of new types of analgesics.